A study led by the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong ...

SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...

Use of sodium-glucose cotransporter-2 inhibitor (SGLT2) drugs should continue in patients with diabetes, in line with current recommendations, conclude the American Association of Clinical ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...

HKUMed reveals that combining novel caFFR imaging technology with glucose lowering drug effectively protects the heart of ...

Some health-obsessed Americans believe the next antiaging therapeutic already exists—in the medicine cabinets of millions of diabetes patients. The widely used class of drugs, called SGLT2 inhibitors ...

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two ...

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...

Recent developments of interest in cardiovascular medicine ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...

A UC San Francisco analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.